Comparison of molecular (BluePrint+MammaPrint) and pathological subtypes for breast cancer among the first 800 patients from the EORTC 10041/BIG 3-04 (MINDACT) trial

Publication Name: SABCS 2012 Poster

Author(s): Giuseppe Viale, Leen Slaets, Femke de Snoo, Laura J. van ‘t Veer, Emiel J. Rutgers, Martine Piccart, Jan Bogaerts, Jeroen van den Akker, Lisette Stork-Sloots, Kristel Engelen, Leila Russo, Patrizia Dell’Orto, Fatima Cardoso

Biology has become the main driver of breast cancer therapy. Intrinsic biological subtypes by gene expression profiling have been identified.  Pathology can be used to define surrogates of these subtypes but these are not always concordant, which may lead to different treatment plans. We investigated the concordance between BluePrint + MammaPrint (micro array based) breast cancer subtypes and pathological surrogates (based on ER, PR, HER2 & Ki67). Contrary to the Perou gene set (evolved into PAM50), BluePrint was trained using pathological data.

See Poster